Kenro Hirata

2.3k total citations
101 papers, 1.8k citations indexed

About

Kenro Hirata is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Kenro Hirata has authored 101 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Surgery, 37 papers in Pulmonary and Respiratory Medicine and 37 papers in Oncology. Recurrent topics in Kenro Hirata's work include Gastric Cancer Management and Outcomes (29 papers), Helicobacter pylori-related gastroenterology studies (23 papers) and Gastrointestinal Tumor Research and Treatment (12 papers). Kenro Hirata is often cited by papers focused on Gastric Cancer Management and Outcomes (29 papers), Helicobacter pylori-related gastroenterology studies (23 papers) and Gastrointestinal Tumor Research and Treatment (12 papers). Kenro Hirata collaborates with scholars based in Japan, United States and Belgium. Kenro Hirata's co-authors include Juntaro Matsuzaki, Toshifumi Hibi∥, Hitoshi Tsugawa, Hidekazu Suzuki, Yoshimasa Saito, Hideyuki Saya, Toshihiro Nishizawa, Osamu Nagano, Yoshikazu Kuroda and Hidekazu Suzuki and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Kenro Hirata

90 papers receiving 1.8k citations

Peers

Countries citing papers authored by Kenro Hirata

Since Specialization

Citations

This map shows the geographic impact of Kenro Hirata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenro Hirata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenro Hirata more than expected).

Fields of papers citing papers by Kenro Hirata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenro Hirata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenro Hirata. The network helps show where Kenro Hirata may publish in the future.

Co-authorship network of co-authors of Kenro Hirata

This figure shows the co-authorship network connecting the top 25 collaborators of Kenro Hirata. A scholar is included among the top collaborators of Kenro Hirata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenro Hirata. Kenro Hirata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan 2026 ·EClinicalMedicine ·Kenro Hirata, (unknown), (unknown), (unknown), Chihiro Kondoh, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Michitaka Nagase, (unknown), (unknown), (unknown), Chiyo K. Imamura, (unknown), (unknown), (unknown)	0
2	Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors 2026 ·Nature Medicine ·(unknown), (unknown), (unknown), Koji Mizuno, Yuichi Ito, (unknown), (unknown), (unknown), (unknown), Takeru Funakoshi, Kenro Hirata, (unknown)	0
3	Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer 2025 ·Journal of Clinical Oncology ·Hisato Kawakami, Shigenori Kadowaki, Akitaka Makiyama, Masahiro Tsuda, Kenro Hirata, Naotoshi Sugimoto, Nozomu Machida, Hiroki Hara, Hidekazu Hirano, Taito Esaki, Yoshito Komatsu, Shuichi Hironaka, Yukari Kobayashi, Kazuhiro Kakimi, Yasutaka Chiba, Narikazu Boku, Ichinosuke Hyodo, (unknown)	2
4	Phase II study of neoadjuvant chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel for resectable esophageal squamous cell carcinoma. 2025 ·Journal of Clinical Oncology ·Shun Yamamoto, Satoru Matsuda, (unknown), Takahiro Tsushima, Akinori Watanabe, Shigenori Kadowaki, Hiroya Takeuchi, Ayumu Hosokawa, Yohei Kubota, Takako Yoshii, Ken Kato, Hiroki Osumi, Masahiro Niihara, Tetsuya Abe, Ryo Takemura, Kenro Hirata, Yasuo Hamamoto, Hirofumi Kawakubo, Yuko Kitagawa	0
5	Clinical characteristics of gastrointestinal stromal tumors with hypoglycemia 2024 ·Oncology Letters ·(unknown), Kenta Kawasaki, (unknown), Hideyuki Hayashi, (unknown), (unknown), (unknown), S. Shimizu, (unknown), (unknown), Yuki Saito, Keitaro Shimozaki, (unknown), Kazuhiro Togasaki, Kenro Hirata, Hiroshi Nishihara, Yae Kanai, Takanori Kanai∥, Yasuo Hamamoto	1
6	1513MO A phase II study of nivolumab plus low dose ipilimumab as first -line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7) 2023 ·Annals of Oncology ·Kei Muro, Hisato Kawakami, Shigenori Kadowaki, Akitaka Makiyama, Masahiro Tsuda, Kenro Hirata, (unknown), Nozomu Machida, Hiroki Hara, Hidekazu Hirano, Taito Esaki, Yoshito Komatsu, Shuichi Hironaka	10
7	An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7) 2021 ·Cancers ·Hisato Kawakami, Shuichi Hironaka, Taito Esaki, Kazuaki Chayama, Masahiro Tsuda, Naotoshi Sugimoto, Shigenori Kadowaki, Akitaka Makiyama, Nozomu Machida, Hidekazu Hirano, Kenro Hirata, Hiroki Hara, Hiroshi Yabusaki, Yoshito Komatsu, Kei Muro	14
8	Analysis of Risk Factors for Immune-Related Adverse Events in Various Solid Tumors Using Real-World Data 2021 ·Future Oncology ·Keitaro Shimozaki, Yasutaka Sukawa, Yasunori Sato, (unknown), (unknown), (unknown), Kazuhiro Togasaki, Kenta Kawasaki, Kenro Hirata, Hideyuki Hayashi, Yasuo Hamamoto, Takanori Kanai∥	16
9	The Entire Intestinal Tract Surveillance Using Capsule Endoscopy after Immune Checkpoint Inhibitor Administration: A Prospective Observational Study 2021 ·Diagnostics ·Keitaro Shimozaki, Kenro Hirata, (unknown), (unknown), (unknown), Yukie Hayashi, Kenta Kawasaki, (unknown), Hideyuki Hayashi, Ryuichi Mizuno, Takeru Funakoshi, Naoki Hosoe, Yasuo Hamamoto, Takanori Kanai∥	2
10	Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis 2020 ·Digestive Diseases and Sciences ·Yukie Hayashi, Naoki Hosoe, Kaoru Takabayashi, Kenji Kamiya, (unknown), Keitaro Shimozaki, Kenro Hirata, (unknown), Seiichiro Fukuhara, Makoto Mutaguchi, Tomohisa Sujino, Yasutaka Sukawa, Yasuo Hamamoto, Makoto Naganuma, Hiromasa Takaishi, Masayuki Shimoda, Haruhiko Ogata, Takanori Kanai∥	28
11	Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group 2020 ·BMC Cancer ·Kenro Hirata, Yasuo Hamamoto, Masahiko Ando, Chiyo K. Imamura, Kenichi Yoshimura, Kentaro Yamazaki, Shuichi Hironaka, Kei Muro	9
12	<p>Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors</p> 2020 ·Cancer Management and Research ·Keitaro Shimozaki, Yasutaka Sukawa, (unknown), Isao Kurihara, Shigeaki Suzuki, Ryuichi Mizuno, Takeru Funakoshi, Shinnosuke Ikemura, (unknown), Kazuhiro Togasaki, Kenta Kawasaki, Kenro Hirata, Hideyuki Hayashi, Yasuo Hamamoto, Hiromasa Takaishi, Takanori Kanai∥	57
13	Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy 2017 ·Cancer Chemotherapy and Pharmacology ·Akiyoshi Kasuga, Yasuo Hamamoto, Ayano Takeuchi, Kenta Kawasaki, Takeshi Suzuki, Kenro Hirata, Yasutaka Sukawa, Hiromasa Takaishi, Takanori Kanai∥	13
14	A Simple and Reliable Method for Intracorporeal Circular-Stapled Esophagojejunostomy Using a Hand-Sewn Over-and-Over Suture Technique in Laparoscopic Total Gastrectomy 2015 ·Annals of Surgical Oncology ·Takeru Matsuda, (unknown), (unknown), Kenro Hirata, Daisuke Tsugawa, Yutaka Sugita, Etsuji Shimada, Yoshihiro Kakeji	1
15	A Three-Step Method for Laparoscopic Mobilization of the Splenic Flexure 2015 ·Annals of Surgical Oncology ·Takeru Matsuda, (unknown), Kenro Hirata, Daisuke Tsugawa, Yutaka Sugita, Yasuo Sumi, Yoshihiro Kakeji	6
16	Validation of the GerdQ questionnaire for the management of gastro‐oesophageal reflux disease in Japan 2013 ·United European Gastroenterology Journal ·Hidekazu Suzuki, Juntaro Matsuzaki, (unknown), Kenro Hirata, Seiichiro Fukuhara, Toshifumi Hibi∥	59
17	Eosinophilic gastroenteritis associated with multiple gastric cancer 2012 ·European Journal of Gastroenterology & Hepatology ·(unknown), (unknown), Takeshi Urade, (unknown), (unknown), Kunio Yokoyama, Kenro Hirata, (unknown), Etsuji Shimada, Masayuki Fujita	7
18	Reactive Oxygen Species-Induced Autophagic Degradation of Helicobacter pylori CagA Is Specifically Suppressed in Cancer Stem-like Cells 2012 ·Cell Host & Microbe ·Hitoshi Tsugawa, Hidekazu Suzuki, Hideyuki Saya, Masanori Hatakeyama, Toshiya Hirayama, Kenro Hirata, Osamu Nagano, Juntaro Matsuzaki, Toshifumi Hibi∥	180
19	Two Amino Acids Mutation of Ferric Uptake Regulator Determines Helicobacter pylori Resistance to Metronidazole 2010 ·Antioxidants and Redox Signaling ·Hitoshi Tsugawa, Hidekazu Suzuki, Kazue Satoh, Kenro Hirata, Juntaro Matsuzaki, Yoshimasa Saito, Makoto Suematsu, Toshifumi Hibi∥	52
20	Etiological difference between ultrashort- and short-segment Barrett’s esophagus 2010 ·Journal of Gastroenterology ·Juntaro Matsuzaki, Hidekazu Suzuki, Keiko Asakura, Yoshimasa Saito, Kenro Hirata, Toru Takebayashi, Toshifumi Hibi∥	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact